The Future of Antibiotics: Is Global South Innovation Our Best Strategy?

Many small companies who are developing new antibiotics are struggling. While progress has been made with respect to creating new incentives, their size has not reached the critical mass that would be required to "pull" innovation in the United States in particular. But if you look broader, there are encouraging developments that are happening. Indian companies are developing new antibacterial treatments. Brazil is fostering its health economic–industrial complex to deliver manufacturing and innovation to deliver universal access to health. South Africa is becoming a competence center for discovery of new antibacterial molecules. In Thailand, Mahidol University is the hot spot for innovation and trials. This session is going to revisit different approaches to innovation in these countries.